A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning Sodium calcium edetate and DMSA in lead poisoning

Clinical Toxicology

Volumn 47, Issue 9, 2009, Pages 841-858

  Bradberry, Sally ^a,b   Vale, Allister ^a,b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

DMSA; Edetate calcium disodium; Lead; Poisoning; Sodium calcium edetate; Succimer; Treatment

Indexed keywords

CARBON 14; EDETATE CALCIUM DISODIUM; SUCCIMER; TECHNETIUM 99M;

BLOOD BRAIN BARRIER; CHELATION; CHELATION THERAPY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INJECTION SITE PAIN; ISOTOPE LABELING; LACRIMATION; LEAD POISONING; MALAISE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; NOSE CONGESTION; PAPULAR RASH; PROTHROMBIN TIME; PRURITUS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SNEEZING; SYSTOLIC BLOOD PRESSURE; T WAVE INVERSION; TISSUE DISTRIBUTION; TREATMENT DURATION; URINARY EXCRETION; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTIDOTES; CHELATING AGENTS; CLINICAL TRIALS AS TOPIC; EDETIC ACID; HUMANS; LEAD; LEAD POISONING; SUCCIMER;

EID: 70350458849     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650903321064     Document Type: Review

References (84)

1. WHO. WHO Model List of Essential Medicines. 15th ed. Geneva: World Health Organisation; 2007.
2. Wang S-C, Ting K-S, Wu C-C. Chelating therapy with Na-DMS in occupational lead and mercury intoxications. Chin Med J (Engl) 1965; 84:437-439.
3. Graziano JH, Siris ES, LoIacono N, Silverberg SJ, Turgeon L. 2,3- Dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther 1985; 37:431-438.
4. Graziano JH, Lolacono NJ, Meyer P. Dose-response study of oral 2,3- dimercaptosuccinic acid in children with elevated blood lead concentrations. J Pediatr 1988; 113:751-757.
5. Fournier L, Thomas G, Garnier R, Buisine A, Houze P, Pradier F, Dally S. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol Adverse Drug Exp 1988; 3:499-504.
6. Bradberry S, Sheehan T, Vale A. Use of oral dimercaptosuccinic acid (succimer; DMSA) in adult patients with inorganic lead poisoning. QJM 2009; 102:721-732.
7. Bradberry S, Vale A. Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning. Clin Toxicol 2009; 47:617-631.
8. Kapoor SC, Wielopolski L, Graziano JH, LoIacono NJ. Influence of 2,3-dimercaptosuccinic acid on gastrointestinal lead absorption and whole-body lead retention. Toxicol Appl Pharmacol 1989; 97:525-529.
9. Tandon SK, Singh S, Jain VK. Efficacy of combined chelation in lead intoxication. Chem Res Toxicol 1994; 7:585-589.
10. Flora GJS, Seth PK, Prakash AO, Mathur R. Therapeutic efficacy of combined meso 2,3-dimercaptosuccinic acid and calcium disodium edetate treatment during acute lead intoxication in rats. Hum Exp Toxicol 1995; 14:410-413.
11. Flora SJS, Bhattacharya R, Vijayaraghavan R. Combined therapeutic potential of meso-2,3-dimercaptosuccinic acid and calcium disodium edetate on the mobilization and distribution of lead in experimental lead intoxication in rats. Fundam Appl Toxicol 1995; 25:233-240.
12. Flora GJS, Seth PK, Kannan GM, Pant BP, Malhotra PR. Combined therapeutic efficacy of few thiols with calcium disodium versenate during acute lead intoxication in mice. Trace Elem Electrolytes 1996; 13:33-36.
13. Flora GJS, Kumar P, Seth PK. Recovery from lead induced biochemical and immunological alterations following combined treatment with DMSA and calcium disodium EDTA in rats. Environ Toxicol Pharmacol 1998; 5:127-134.
14. Bradberry SM. The Role of Succimer (DMSA) in the Treatment of Inorganic Lead Poisoning. Birmingham, UK: University of Birmingham; 2009.
15. 14 labeled ethylenediaminetetraacetic acid in human beings. J Lab Clin Med 1954; 43:566-571.
16. Klaassen CD. Heavy metals and heavy-metal antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:1649-1671.
17. Jones MM. Chemistry of chelation: chelating agent antagonists for toxic metals. In: Goyer RA, Cherian MG, eds. Toxicology of Metals: Biochemical Aspects (Born GVR, Cuatrecasas P, Ganten D, Herken H, Melmon KL, eds. Handbook of experimental pharmacology). Heidelberg: Springer Verlag; 1995:279-304.
18. Leckie WJH, Tompsett SL. The diagnostic and therapeutic use of edathamil calcium-disodium (EDTA, versene) in excessive inorganic lead absorption. QJM 1958; 27:65-82.
19. Osterloh J, Becker CE. Pharmacokinetics of CaNa2-EDTA and chelation of lead in renal failure. Clin Pharmacol Ther 1986; 40:686-693.
20. 14-labeled ethylenediamine- tetraacetic acid in the rat. J Biol Chem 1953; 203:1045-1053.
21. Miller CR, Zhu S-Y, Victery W, Goyer RA. Partitioning of renal zinc between metallothionein and ethylenediaminetetraacetic acid (EDTA) after treatment of rats with Ca(Na)2EDTA. Toxicol Appl Pharmacol 1986; 84:584-592.
22. Goyer RA, Wilson MH. Lead induced inclusion bodies. Results of ethylenediaminetetraacetic acid treatment. Lab Invest 1975; 32:149-156.
23. Sweetman SC, Blake PS, Neathercoat GC, Parsons AV, eds. Martindale: The Complete Drug Reference. 35th ed. London: The Pharmaceutical Press; 2007.
24. Dollery C, ed. Therapeutic Drugs. 2nd ed. London: Churchill Livingstone; 1999.
25. Hammond PB, Aronson AL, Olson WC. The mechanism of mobilization of lead by ethylenediaminetetraacetate. J Pharmacol Exp Ther 1967; 157:196-206.
26. Cory-Slechta DA, Weiss B, Cox C. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. J Pharmacol Exp Ther 1987; 243:804-813.
27. Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 2003; 146:95-158.
28. McGown EL, Tillotson JA, Knudsen JJ, Dumlao CR. Biological behavior and metabolic fate of the BAL analogues DMSA and DMPS. Proc West Pharmacol Soc 1984; 27:169-176.
29. Maiorino RM, Akins JM, Blaha K, Carter DE, Aposhian HV. Determination and metabolism of dithiol chelating agents: X. In humans, meso- 2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation. J Pharmacol Exp Ther 1990; 254:570-577.
30. Tillotson JA, Boswell G, Kincannon L, Speckman CL. The biological fate of 14C-dimercaptosuccinic acid in monkeys and rabbits. Mil Med 1989; 154:444-449.
31. Asiedu P, Moulton T, Blum CB, Roldan E, Lolacono NJ, Graziano JH. Metabolism of meso-2,3-dimercaptosuccinic acid in lead-poisoned children and normal adults. Environ Health Perspect 1995; 103:734-739.
32. Aposhian HV, Maiorino RM, Rivera M, Bruce DC, Dart RC, Hurlbut KM, Levine DJ, Zheng W, Fernando Q, Carter D, Aposhian MM. Human studies with the chelating agents, DMPS and DMSA. J Toxicol Clin Toxicol 1992; 30:505-528.
33. 14C] dimercaptosuccinic acid in mice. Fundam Appl Toxicol 1986; 6:532-540.
34. +-dependent dicarboxylate transporter, NaDC-3, translocates dimethyl- and disulfhydryl-compounds and contributes to renal heavy metal detoxification. J Am Soc Nephrol 2002; 13:2628-2638.
35. 99mTc- DMSA in the rat. Eur J Nucl Med 1990; 16:29-34.
36. Provoost AP, Van Aken M. The effect of DMSA loading on the renal handling of technetium-99 m in rats. Uremia Invest 1985; 9:147-150. (Pubitemid 16039458)
37. Maiorino RM, Bruce DC, Aposhian HV. Determination and metabolism of dithiol chelating agents. VI. Isolation and identification of the mixed disulfides of meso-2,3-dimercaptosuccinic acid with L-cysteine in human urine. Toxicol Appl Pharmacol 1989; 97:338-349.
38. Aposhian HV, Maiorino RM, Dart RC, Perry DF. Urinary excretion of meso-2,3-dimercaptosuccinic acid in human subjects. Clin Pharmacol Ther 1989; 45:520-526.
39. Dart RC, Hurlbut KM, Maiorino RM, Mayersohn M, Aposhian HV, Hassen LVB. Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. J Pediatr 1994; 125:309-316.
40. Maiorino RM, Aposhian MM, Xu Z-F, Li Y, Polt RL, Aposhian HV. Determination and metabolism of dithiol chelating agents. XV. The meso-2,3-dimercaptosuccinic acid-cysteine (1:2) mixed disulfide, a major urinary metabolite of DMSA in the human, increases the urinary excretion of lead in the rat. J Pharmacol Exp Ther 1993; 267:1221-1226.
41. Rabinowitz MB. Toxicokinetics of bone lead. Environ Health Perspect 1991; 91:33-37.
42. Banner W Jr, Koch M, Capin DM, Hopf SB, Chang S, Tong TG. Experimental chelation therapy in chromium, lead and boron intoxication with N-acetylcysteine and other compounds. Toxicol Appl Pharmacol 1986; 83:142-147.
43. Flora SJS, Tandon SK. Beneficial effects of zinc supplementation during chelation treatment of lead intoxication in rats. Toxicology 1990; 64:129-139.
44. Flora SJS. Influence of simultaneous supplementation of zinc and copper during chelation of lead in rats. Hum Exp Toxicol 1991; 10:331-336.
45. Tandon SK, Singh S, Prasad S, Mathur N. Mobilization of lead by calcium versenate and dimercaptosuccinate in the rat. Clin Exp Pharmacol Physiol 1998; 25:686-692.
46. Graziano JH, Leong JK, Friedheim E. 2,3-dimercaptosuccinic acid: a new agent for the treatment of lead poisoning. J Pharmacol Exp Ther 1978; 206:696-700. (Pubitemid 9008473)
47. Llobet JM, Domingo JL, Paternain JL, Corbella J. Treatment of acute lead intoxication. A quantitative comparison of a number of chelating agents. Arch Environ Contam Toxicol 1990; 19:185-189. (Pubitemid 20096856)
48. Friedheim E, Graziano J, Popovac D, Dragovic D, Kaul B. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet, 1978; 2:1234-1236.
49. Graziano JH, LoIacono NJ, Moulton T, Mitchell ME, Slavkovich V, Zarate C. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J Pediatr 1992; 120:133-139.
50. Lee B-K, Schwartz BS, Stewart W, Ahn K-D. Provocative chelation with DMSA and EDTA: evidence for differential access to lead storage sites. Occup Environ Med 1995; 52:13-19.
51. Bankowska J, Hine C. Retention of lead in the rat. Arch Environ Contam Toxicol 1985; 14:621-629.
52. Flora GJS, Seth PK, Flora SJS. Recoveries in lead induced alterations in rat brain biogenic amines levels following combined chelation therapy with meso 2,3-dimercaptosuccinic acid and calcium disodium versenate. Biog Amines 1997; 13:79-90.
53. Denver MC, Tell LA, Galey FD, Trupkiewicz JG, Kass PH. Comparison of two heavy metal chelators for treatment of lead toxicosis in cockatiels. Am J Vet Res 2000; 61:935-940.
54. Jones MM, Basinger MA, Gale GR, Atkins LM, Smith AB, Stone A. Effect of chelate treatments on kidney, bone and brain lead levels of lead-intoxicated mice. Toxicology 1994; 89:91-100.
55. Xu Z-F, Jones MM. Comparative mobilization of lead by chelating agents. Toxicology 1988; 53:277-288.
56. Friedheim E, Corvi C, Wakker CH. Meso-dimercaptosuccinic acid a chelating agent for the treatment of mercury and lead poisoning. J Pharm Pharmacol 1976; 28:711-712.
57. Kostial K, Blanusa M, Piasek M, Restek-Samarzija N, Jones MM, Singh PK. Combined chelation therapy in reducing tissue lead concentrations in suckling rats. J Appl Toxicol 1999; 19:143-147.
58. 2+. J Pharmacol Exp Ther 2007; 322:108-116.
59. Meldrum JB, Ko KW. Effects of calcium disodium EDTA and meso- 2,3-dimercaptosuccinic acid on tissue concentrations of lead for use in treatment of calves with experimentally induced lead toxicosis. Am J Vet Res 2003; 64:672-676.
60. Shrand H. Treatment of lead poisoning with intramuscular edathamil calcium-disodium. Lancet 1961; 1:310-312.
61. Markus AC, Spencer AG. Treatment of chronic lead-poisoning with calcium disodium versenate. Br Med J 1955; 2:883-885.
62. Byers RK, Maloof C. Edathamil calcium-disodium (versenate) in treatment of lead poisoning in children. Am J Dis Child 1954; 87:559-569.
63. Bessman SP, Rubin M, Leikin S. The treatment of lead encephalopathy - a method for the removal of lead during the acute stage. Pediatrics 1954; 14:201-208.
64. Karpinski FE Jr, Rieders F, Girsh LS. Calcium disodium versenate in the therapy of lead encephalopathy. J Pediatr 1953; 42:687-699.
65. Byers RK. Lead poisoning. Review of the literature and report on 45 cases. Pediatrics 1959; 23:585-603.
66. Whitfield CL, Ch'ien LT, Whitehead JD. Lead encephalopathy in adults. Am J Med 1972; 52:289-298.
67. Rae CE, Bell CN Jr, Elliott CE, Shannon M. Ten cases of acute lead intoxication among bridge workers in Louisiana. Ann Pharmacother 1991; 25:932-937.
68. Reuber MD, Bradley JE. Acute versenate nephrosis occurring as the result of treatment for lead intoxication. JAMA 1960; 174:263-269.
69. Vogt W, Cottier H. Nekrotisierende Nephrose nache Behandlung einer subakutchronischen Bleivergiftung mit Versenat in hohen Dosen. Schweiz Med Wochenschr 1957; 87:665-667.
70. Wedeen RP, Batuman V, Landy E. The safety of the EDTA leadmobilization test. Environ Res 1983; 30:58-62.
71. Moel DI, Kumar K. Reversible nephrotoxic reactions to a combined 2,3-dimercapto-1-propanol and calcium disodium ethylenediaminetetraacetic acid regimen in asymptomatic children with elevated blood lead levels. Pediatrics 1982; 70:259-262.
72. Yver L, Maréchaud R, Picaud D, Touchard G, Talin d'Eyzac A, Matuchansky C, Patte D. Insuffisance rénale aiguë au cours d'un saturnisme professionel. Responsabilité du traitement chélateur. Nouv Presse Med 1978; 7:1541-1543.
73. Araki S, Aono H, Murata K. Mobilisation of heavy metals into the urine by CaEDTA: relation to erythrocyte and plasma concentrations and exposure indices. Br J Ind Med 1986; 43:636-641.
74. Thomas DJ, Chisolm JJ Jr. Lead, zinc and copper decorporation during calcium disodium ethylenediamine tetraacetate treatment of leadpoisoned children. J Pharmacol Exp Ther 1986; 239:829-835.
75. Chisolm JJ. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. J Toxicol Clin Toxicol 2000; 38:365-375.
76. Lech T, Sadlik JK. Contribution to the data on copper concentration in blood and urine in patients with Wilson's disease and in normal subjects. Biol Trace Elem Res 2007; 118:16-20.
77. Torres-Alanís O, Garza-Ocañas L, Piñeyro-López A. Effect of meso- 2,3-dimercaptosuccinic acid on urinary lead excretion in exposed men. Hum Exp Toxicol 2002; 21:573-577.
78. Liebelt EL, Shannon M, Graef JW. Efficacy of oral meso-2,3- dimercaptosuccinic acid therapy for low-level childhood plumbism. J Pediatr 1994; 124:313-317.
79. Perry HM Jr, Shroeder HA. Lesions resembling vitamin B complex deficiency and urinary loss of zinc produced by ethylenediamine tetraacetate. Am J Med 1957; 24:168-172.
80. Gordon JN, Taylor A, Bennett PN. Lead poisoning: case studies. Br J Clin Pharmacol 2002; 53:451-458.
81. Grandjean P, Jacobsen IA, Jørgensen PJ. Chronic lead poisoning treated with dimercaptosuccinic acid. Pharmacol Toxicol 1991; 68:266-269.
82. Lee A, ed. Adverse Drug Reactions. 2nd ed. London: Pharmaceutical Press; 2006.
83. Gerr F, Frumkin H, Hodgins P. Hemolytic anemia following succimer administration in a glucose-6-phosphate dehydrogenase deficient patient. J Toxicol Clin Toxicol 1994; 32:569-575.
84. Besunder JB, Anderson RL, Super DM. Short-term efficacy of oral dimercaptosuccinic acid in children with low to moderate lead intoxication. Pediatrics 1995; 96:683-687.